2011
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy
Morris PG, Abrey LE, Reiner AS, Wu N, Panageas KS, Seko BS, Deangelis LM, Omuro A. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leukemia & Lymphoma 2011, 52: 1891-1897. PMID: 21699456, DOI: 10.3109/10428194.2011.585527.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCentral Nervous System NeoplasmsCombined Modality TherapyCytarabineFemaleHumansKarnofsky Performance StatusMaleMethotrexateMiddle AgedProcarbazinePrognosisRituximabSurvival AnalysisVincristineConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaProgression-free survivalNervous system lymphomaMTX AUCMethotrexate areaSystem lymphomaMedian Karnofsky performance status (KPS) scoreIntra-patient dose escalationProspective phase II trialKarnofsky performance status scoreLow-dose radiotherapyFirst chemotherapy cyclePerformance status scorePhase II trialImproved tumor controlSubstantial inter-individual variabilityChemotherapy cyclesII trialMTX exposureOverall survivalDose escalationMedian agePrognostic factorsInter-individual variability
2010
Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL).
Morris P, Abrey L, Reiner A, Panageas K, Seko B, DeAngelis L, Omuro A. Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL). Journal Of Clinical Oncology 2010, 28: 2040-2040. DOI: 10.1200/jco.2010.28.15_suppl.2040.Peer-Reviewed Original Research